Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use - Supplemental Tables.docx

Supplementary Table 1: Patient demographic characteristics and prescriber specialty <br> Supplementary Table 2: Baseline comorbidities <br> Supplementary Table 3: Baseline medication use <br> Supplementary Table 4: Baseline healthcare utilization, and costs <br> Supplementary Table 5: Number of index medication fills before biologic initiation during the 1-year follow-up period <br> Supplementary Table 6: First biologic medication used during the 1-year follow-up period among apremilast patients who initiated biologic <br> Supplementary Table 7: First biologic medication used during the 1-year follow-up period among methotrexate patients who initiated biologic <br> Supplementary Table 8: Biologic initiation adjusted results

补充表1：患者人口统计学特征及处方医生专业<br>补充表2：基线合并症<br>补充表3：基线用药情况<br>补充表4：基线医疗资源利用及成本<br>补充表5：1年随访期间生物制剂启动前的索引药物处方填充次数<br>补充表6：启动生物制剂的阿普斯特患者在1年随访期间使用的首个生物制剂药物<br>补充表7：启动生物制剂的甲氨蝶呤患者在1年随访期间使用的首个生物制剂药物<br>补充表8：生物制剂启动的校正结果